ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $51.240 million which beat the analyst consensus estimate of $49.700 million by 3.10 percent. This is a 93.91 percent increase over sales of $26.425 million the same period last year.